FOXO4-DRI is a D-retro-inverso peptide designed to selectively target and clear senescent cells, which accumulate with age and contribute to tissue dysfunction. It works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive, potentially triggering selective apoptosis of these aged, dysfunctional cells.
Category: Anti-Aging & Longevity. Evidence rating: D (animal/preclinical only).
Clinical status: Preclinical only. Single landmark mouse study (Baar et al., Cell 2017). No human clinical trials.
Disrupts the FOXO4-p53 protein-protein interaction in senescent cells. Normally, FOXO4 sequesters p53 in the nucleus of senescent cells, preventing apoptosis. FOXO4-DRI competes with endogenous FOXO4, freeing p53 to trigger mitochondrial apoptosis specifically in senescent cells while sparing…
Safety considerations: No human safety data exists; Theoretical risk of off-target apoptosis in non-senescent cells; Extremely limited preclinical characterization.
Reviewed by the PeptideAtlas Editorial Team.
| Molecular weight | ~4.8 kDa |
|---|---|
| Production method | synthetic |
| US regulatory status | Research compound only. No regulatory status. |
Unknown. The only published study was in mice (Baar et al., Cell 2017). No human trials have been conducted. Self-experimentation carries significant unknown risks.
A peptide where all L-amino acids are replaced with D-amino acids and the sequence is reversed. This creates a peptide with similar side chain topology to the original but with enhanced protease resistance.
FOXO4-DRI is a D-retro-inverso peptide designed to selectively target and clear senescent cells, which accumulate with age and contribute to tissue dysfunction. It works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive, potentially triggering selective apoptosis of these aged, dysfunctional cells.
On the PeptideAtlas A–F scale, FOXO4-DRI is rated D (Preclinical Only). Mostly animal or preclinical evidence
Preclinical only. Single landmark mouse study (Baar et al., Cell 2017). No human clinical trials.
Vendors stocking it: OP Labs, Reta-Peptide, Zztai Peptide, Mei Peptide, Pacific Peptide, ZestyRat Research, VitalCell Peptides, Catalyst Peptides, Bluewell Peptides, Growth Guys, Advanced Peptides Australia, Orbitrex Peptides, Dankang BioHealth, Wuhan Newtop Biotech, Prime Source, Hengan Peptide Factory, Topstide, Optimun Compounds.